SEP 13, 2019 7:46 AM PDT

Cancer drugs don't work the way we thought

New research recently published in the journal Science Translational Medicine surprises the oncological community with findings that a protein previously thought to influence cancer growth actually has no impact on cancer cells at all.

The research was conducted by scientists at Cold Spring Harbor Laboratory (CSHL) led by Jason Sheltzer and focused on a protein called MELK. MELK is often found in high levels in tumors and has been thought to play a significant role in cancer cells. But after using CRISPR to shut off MELK production, the scientists found that the cancer cells were unaffected. "To our great surprise, the cancer cells didn't die," Sheltzer reported last year. "They just didn't care about MELK."

And it turns out that MELK wasn’t alone. In further investigations, Sheltzer’s lab, joined by researchers Ann Lin and Chris Giuliano, figured out ten other drugs whose “mechanism of action” had also previously been mischaracterized. Each of the ten drugs are currently in the process of clinical trials with approximately 1000 human cancer patients in total.

"The idea for many of these drugs is that they block the function of a certain protein in cancer cells. And what we showed is that most of these drugs don't work by blocking the function of the protein that they were reported to block," Sheltzer explained. "So that's what I mean when I talk about mechanism of action."

One of the drugs that Sheltzer’s team debunked was one that was thought to kill cancer cells by inhibiting the protein PBK. However, after exposing cancer cells to high levels of the drug, they found that the drug’s interaction with PBK wasn’t actually responsible. "It turns out that this interaction with PBK has nothing to do with how it actually kills cancer cells," Sheltzer said. Instead, they found that a protein called CDK11 is the real mechanism of action against cancer.

Researchers are surprised by cancer drugs' mechanism of action. Photo: Pixabay

The researchers hope that their findings will steer drug discovery in a new direction in order to improve personalized medicine. "A lot of drugs that get tested in human cancer patients tragically don't end up helping cancer patients," Sheltzer said. "If this kind of evidence was routinely collected before drugs entered clinical trials, we might be able to do a better job assigning patients to therapies that are most likely to provide some benefit. With this knowledge, I believe we can better fulfill the promise of precision medicine."

Sources: Science Daily, Science Translational Medicine

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 20, 2019
Immunology
NOV 20, 2019
Harnessing the Power of Natural Killer Cells to Fight Cancer
Manipulating the immune system’s population of natural killer cells could bolster therapies targeting cancer. A new study saw positive results invest...
JAN 15, 2020
Clinical & Molecular DX
JAN 15, 2020
Laser microchip picks up cancer markers in urine
A future where patients no longer need to endure expensive, painful and complicated cancer tests could soon become a reality. Researchers have developed a...
JAN 20, 2020
Neuroscience
JAN 20, 2020
Ovarian Cancer Protein Accelerates Alzheimer's Neurodegeneration
Around 21,000 people in the US are diagnosed with ovarian cancer every year, while an estimated 5.8 million Americans have Alzheimer’s. Now, research...
JAN 21, 2020
Cannabis Sciences
JAN 21, 2020
Medical Marijuana Ineffective for Long Term Pain Management
Medicinal cannabis may not as effective as once thought as a solution for sleep problems for those with chronic pain in the long run, according to new find...
FEB 02, 2020
Cell & Molecular Biology
FEB 02, 2020
New T Cell Therapy is a Universal Approach to Target Cancer
For years, researchers have been trying to harness the power of the assassins of the immune system - killer T cells....
FEB 14, 2020
Immunology
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses agains...
Loading Comments...